Br[C:2]1[CH:3]=[N:4][C:5]([O:8][CH2:9][CH2:10][O:11][C:12]2[C:16]([C:17]3[CH:22]=[CH:21][C:20]([CH3:23])=[CH:19][CH:18]=3)=[C:15]([NH:24][S:25]([C:28]3[CH:33]=[CH:32][C:31]([CH:34]([CH3:36])[CH3:35])=[CH:30][N:29]=3)(=[O:27])=[O:26])[N:14]([CH3:37])[N:13]=2)=[N:6][CH:7]=1.C([O-])=O.[Na+].[C]=O>Cl[Pd](Cl)([P](C1C=CC=CC=1)(C1C=CC=CC=1)C1C=CC=CC=1)[P](C1C=CC=CC=1)(C1C=CC=CC=1)C1C=CC=CC=1.CN(C)C=O>[CH:34]([C:31]1[CH:32]=[CH:33][C:28]([S:25]([NH:24][C:15]2[N:14]([CH3:37])[N:13]=[C:12]([O:11][CH2:10][CH2:9][O:8][C:5]3[N:4]=[CH:3][CH:2]=[CH:7][N:6]=3)[C:16]=2[C:17]2[CH:22]=[CH:21][C:20]([CH3:23])=[CH:19][CH:18]=2)(=[O:26])=[O:27])=[N:29][CH:30]=1)([CH3:36])[CH3:35]N-[3-{2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy}-1-methyl-4-(4-methylphenyl)-1H-pyrazol-5-yl]-5-isopropylpyridine-2-sulfonamide (Example 41) (393 mg), powdered sodium formate (68 mg) and dichlorobis(triphenylphosphine)palladium (II) (9.4 mg) were placed in a Wheaton® vial (2.5 ml) volume containing a stirring vane. Dimethylformamide (2.0 ml) which had been saturated with carbon monoxide gas at room temperature, was added to the vial so as to produce a yellow solution. The sealed vial was magnetically stirred at 100° C. (oil bath temperature) for 3 hours before being left to cool to room temperature. A TLC check showed the presence of a significant amount of starting material. Addition of dichlorobis(triphenylphosphine)palladium (II) (9.4 mg) and resaturation of the dimethylformamide with carbon monoxide was followed by heating of the vial's contents for a further hour. On cooling to room temperature, the solution was degassed by bubbling nitrogen gas through it. The mixture was treated with ethyl acetate and filtered through a bed of Celite™ (5 g), followed by washing the Celite with ethyl acetate so as to take the solution volume to 100 ml. Washing of this phase with water (3×100 ml) and brine (100 ml), was followed by drying (Na2SO4), filtering and concentration in vacuo. This afforded the title compound as white crystals (157 mg).
Wird geladen…